A Phase 1 interventional study of ARC-AAT Injection and Placebo in Alpha-1 Antitrypsin Deficiency, sponsored by Arrowhead Pharmaceuticals. Terminated at 4 sites in 4 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Arrowhead Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia — 7 open to participants now, 8 under way, 2 of them phase 3. alpha 1-Antitrypsin Deficiency · Australia.
Among the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, this one is the 11th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1, and was the 6th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →7 of the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia are open now. Recruiting first, the newest first:
CRISPR Therapeutics · Sites in Australia
Ages 18–75
Tessera Therapeutics, Inc. · Sites in Australia, United States, Netherlands and 2 more countries
Ages 18–70
AIRNA Corporation · Sites in Australia, Georgia, Germany and 6 more countries
Ages 18–74
Wave Life Sciences USA, Inc. · Sites in Australia, Canada, Finland and 3 more countries
Ages 18–70
Beam Therapeutics Inc. · Sites in Australia, United States, Ireland and 3 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 2005; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 70 across the 18 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 13 (54%) have results posted.
Arrowhead Pharmaceuticals has 5 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
1 of the studies in alpha 1-Antitrypsin Deficiency with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06405633Wave Life Sciences USA, Inc.A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the safety and tolerability of escalating doses of ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on circulating levels of alpha-1 antitrypsin (AAT). The study will consist of two parts, Part A (conducted in healthy volunteers) and Part B (conducted in AATD patients) at up to 9 escalating dose levels with 6 participants per dose level.
Healthy volunteers and AATD patients will be randomized to receive a single intravenous injection of either ARC-AAT or Placebo in double-blind fashion. Up to thirteen cohorts (6 participants per cohort) will be enrolled. Participants in all cohorts will be confined to the clinical facility beginning on Day -1 with discharge on Day 2. Escalation to the next dose level will proceed until a participant experiences a dose-limiting toxicity (DLT) or there is achievement of pre-determined threshold reductions in AAT levels. Dosing in participants with AATD will commence based on pre-determined threshold reductions in AAT levels for healthy volunteers. For each participant, the duration of the study clinic visits is up to 11 weeks, from Screening to the End-of-Study examination. However, including a Day 90 Follow-Up telephone call, the maximum study duration is approximately 20 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(Part A - Healthy Volunteers)
(Part B-Patients) - As for Part A with the following exceptions:
Exclusion Criteria:
(Part A-Healthy Volunteers)
(Part B-Patients) - As for Part A with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of 0.9% normal saline IV injection in healthy volunteers
Other: Placebo · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
Drug: ARC-AAT Injection · Drug: Diphenhydramine
Single dose administration of 0.9% normal saline IV injection in participants with AATD
Other: Placebo · Drug: Diphenhydramine
RNA interference-based, liver-targeted therapeutic
Also known as: ARC-AAT
0.9 % normal saline
Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs
An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. SAEs are defined as is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.
Time frame: From the first dose of study treatment through Day 29 ± 1 day
Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values
Laboratory values collected include: hematology (haemoglobin, lymphocytes, neutrophils, platelets, white cell count, monocytes); biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, creatine kinase, creatinine, gamma-glutamyltransferase, fasting glucose, troponin I); coagulation parameters (fibrinogen, international normalized ratio); and C-reactive protein.
Time frame: Day 1 through Day 29 ± 1 day
Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations
Values collected include: vital signs (clinically concerning or symptomatic treatment emergent changes in heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, or temperature); ECGs (clinically significant changes from baseline were observed for ventricular rate, RR interval, QRS duration, QT interval or QT interval corrected for heart rate using Fridericia's formula \[QTcF\]; treatment emergent clinically significant changes in ST segments, P wave or T wave morphology; cardiac telemetry monitoring); clinically significant abnormal physical examination findings; treatment emergent sensitivity to bee venom; pulmonary function (clinically significant worsening in spirometry parameters and carbon monoxide diffusing capacity of the lung for carbon monoxide \[DLCO\]).
Time frame: Day 1 through Day 29 ± 1 day
Pharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)
Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Pharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Pharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Pharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Percentage Reduction From Baseline of AAT Up to Day 29
Clinical assay for total serum AAT level was used for Part A. A quantitative measurement of AAT was used for Part B. A negative percent reduction indicates a percentage increase. Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.
Time frame: Baseline, Days 3, 8, 15, 22 and 29
Number of Participants With AAT Reduction > 30% From Baseline (First Occurrence)
Data presents the study visit day upon which a participant had the first occurrence of AAT reduction of \> 30% from Baseline, and the number of participants who had a \> 30% reduction at any visit (overall). Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.
Time frame: Baseline, Days 3, 8, 15, 22 and 29
Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)
Time frame: Study Day for Nadir of Mean AAT: Day 8 (for Part B 2 mg/kg arm), Day 15 (for Part A 0.38 mg/kg, 2 mg/kg, 4 mg/ kg, Placebo arms; Part B 4 mg/kg, Placebo arms), Day 22 (Part A 3 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg arms), Day 29 (1 mg/kg, 8 mg/kg arms)
Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in > 100 Days
Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.
Time frame: Baseline, up to Day 29, and through 100 days of follow-up
Mean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose
Time frame: Pre-dose, 2 hours post-dose
Mean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose
Time frame: Pre-dose, 2 hours post-dose
| Milestone | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 18 | 4 | 3 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 18 | 4 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. SAEs are defined as is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.
| participants | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 1 | 3 | 9 | 3 | 2 | 4 |
| Study Drug Related TEAEs | 1 | 1 | 2 | 1 | 1 | 2 | 0 | 0 | 3 | 1 | 1 | 0 | 0 |
| Mild or Moderate TEAEs | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 1 | 3 | 8 | 3 | 2 | 4 |
| Severe TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Study Drug Related Moderate TEAEs | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Study Drug Related Severe TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Discontinuations Due to TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Laboratory values collected include: hematology (haemoglobin, lymphocytes, neutrophils, platelets, white cell count, monocytes); biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, creatine kinase, creatinine, gamma-glutamyltransferase, fasting glucose, troponin I); coagulation parameters (fibrinogen, international normalized ratio); and C-reactive protein.
| participants | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Troponin I | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatine Kinase | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White Cell Count | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Monocytes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Red Cell Distribution Width | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Values collected include: vital signs (clinically concerning or symptomatic treatment emergent changes in heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, or temperature); ECGs (clinically significant changes from baseline were observed for ventricular rate, RR interval, QRS duration, QT interval or QT interval corrected for heart rate using Fridericia's formula \[QTcF\]; treatment emergent clinically significant changes in ST segments, P wave or T wave morphology; cardiac telemetry monitoring); clinically significant abnormal physical examination findings; treatment emergent sensitivity to bee venom; pulmonary function (clinically significant worsening in spirometry parameters and carbon monoxide diffusing capacity of the lung for carbon monoxide \[DLCO\]).
| participants | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ECGs | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Physical Examination Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Bee Venom Sensitivity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulmonary Function | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| ng/mL | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Analyte AD00370 | 4430 ± 1175 | 15500 ± 2811 | 32400 ± 7005 | 50650 ± 7461 | 75625 ± 8152 | 93275 ± 6133 | 115750 ± 11871 | 130250 ± 14127 | 167000 ± 7810 |
| Analyte ARC-MLP | 2760 ± 508 | 9350 ± 2368 | 20700 ± 3334 | 27050 ± 5390 | 43425 ± 3872 | 48975 ± 5590 | 70050 ± 6946 | 62525 ± 4029 | 84733 ± 2875 |
| hour | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Analyte AD00370 | 0.083 (0.083 to 0.25) | 0.083 (0.083 to 0.083) | 0.083 (0.083 to 0.083) | 0.083 (0.083 to 0.50) | 0.083 (0.083 to 0.083) | 0.083 (0.083 to 0.50) | 0.083 (0.083 to 0.50) | 0.083 (0.083 to 0.50) | 0.50 (0.083 to 0.50) |
| Analyte ARC-MLP | 0.083 (0.083 to 0.25) | 0.083 (0.083 to 0.083) | 0.083 (0.083 to 0.083) | 0.083 (0.083 to 0.083) | 0.083 (0.083 to 0.50) | 0.083 (0.083 to 0.50) | 0.083 (0.083 to 1.00) | 0.50 (0.083 to 1.00) | 0.50 (0.50 to 0.50) |
| hr*ng/mL | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Analyte AD00370 | 26905 ± 10793 | 85138 ± 12234 | 162198 ± 56129 | 282710 ± 61810 | 438532 ± 38111 | 541628 ± 49787 | 708648 ± 212442 | 763392 ± 96095 | 908117 ± 144892 |
| Analyte ARC-MLP | 28734 ± 6757 | 82627 ± 32332 | 213250 ± 67886 | 291876 ± 58240 | 458790 ± 48790 | 459939 ± 81820 | 699833 ± 85172 | 716938 ± 46783 | 1011569 ± 101693 |
| hr*ng/mL | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Analyte AD00370 | 27388 ± 11183 | 85906 ± 12529 | 164856 ± 58070 | 285487 ± 62310 | 441239 ± 39032 | 547045 ± 52126 | 719843 ± 226599 | 771924 ± 100469 | 916343 ± 147924 |
| Analyte ARC-MLP | 34718 ± 8345 | 103116 ± 48837 | 277684 ± 119873 | 380506 ± 89117 | 559372 ± 82769 | 569056 ± 129569 | 872798 ± 136277 | 952668 ± 99324 | 1251318 ± 138571 |
| 1/hour | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Analyte AD00370 | 0.186 ± 0.050 | 0.177 ± 0.004 | 0.170 ± 0.013 | 0.174 ± 0.004 | 0.185 ± 0.011 | 0.183 ± 0.006 | 0.185 ± 0.023 | 0.178 ± 0.010 | 0.181 ± 0.009 |
| Analyte ARC-MLP | 0.0786 ± 0.0141 | 0.0879 ± 0.0297 | 0.0778 ± 0.0265 | 0.0762 ± 0.0218 | 0.0846 ± 0.0158 | 0.0815 ± 0.0231 | 0.0768 ± 0.0104 | 0.0622 ± 0.0077 | 0.0730 ± 0.0046 |
| hours | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Analyte AD00370 | 3.90 ± 0.84 | 3.91 ± 0.09 | 4.09 ± 0.31 | 3.99 ± 0.09 | 3.75 ± 0.22 | 3.78 ± 0.12 | 3.80 ± 0.53 | 3.90 ± 0.23 | 3.83 ± 0.19 |
| Analyte ARC-MLP | 9.02 ± 1.50 | 8.60 ± 2.88 | 9.77 ± 3.39 | 9.83 ± 3.46 | 8.43 ± 1.68 | 8.93 ± 1.98 | 9.17 ± 1.40 | 11.3 ± 1.5 | 9.52 ± 0.61 |
Clinical assay for total serum AAT level was used for Part A. A quantitative measurement of AAT was used for Part B. A negative percent reduction indicates a percentage increase. Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.
| percentage reduction | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 3 | -4.70 ± 8.45 | -7.00 ± 3.19 | -1.94 ± 4.49 | 13.76 ± 4.74 | 20.76 ± 5.86 | 21.65 ± 5.28 | 22.20 ± 8.80 | 20.35 ± 11.83 | 30.07 ± 6.37 | -4.65 ± 11.13 | 11.5 ± 11.5 | 43.8 ± 5.6 | -13.0 ± 31.9 |
| Day 8 | 0.93 ± 2.86 | 10.90 ± 8.30 | 13.40 ± 11.68 | 33.20 ± 14.33 | 46.92 ± 6.16 | 58.52 ± 6.15 | 58.44 ± 7.50 | 50.95 ± 6.82 | 58.66 ± 2.99 | -0.26 ± 10.80 | 43.1 ± 26.7 | 54.4 ± 22.2 | 7.0 ± 36.9 |
| Day 15 | 5.00 ± 2.62 | 3.89 ± 2.78 | 26.72 ± 14.31 | 33.65 ± 14.66 | 61.53 ± 11.75 | 74.20 ± 7.03 | 75.75 ± 5.95 | 73.57 ± 2.76 | 79.18 ± 4.03 | 0.78 ± 11.91 | 37.5 ± 20.4 | 77.7 ± 1.5 | 7.2 ± 19.8 |
| Day 22 | 1.42 ± 4.01 | 6.81 ± 8.81 | 15.59 ± 9.21 | 35.50 ± 15.24 | 58.64 ± 13.55 | 77.18 ± 9.94 | 83.12 ± 3.67 | 81.14 ± 1.17 | 87.47 ± 2.09 | 0.50 ± 13.48 | 25.1 ± 17.2 | 59.5 ± 13.4 | 1.7 ± 20.8 |
| Day 29 | 0.19 ± 10.37 | 25.87 ± 6.58 | 13.93 ± 17.16 | 27.40 ± 10.65 | 50.02 ± 20.46 | 73.15 ± 14.46 | 82.99 ± 4.19 | 78.20 ± 7.83 | 87.93 ± 1.75 | -1.56 ± 8.66 | 21.0 ± 24.4 | 65.2 ± 8.7 | -7.2 ± 30.3 |
Data presents the study visit day upon which a participant had the first occurrence of AAT reduction of \> 30% from Baseline, and the number of participants who had a \> 30% reduction at any visit (overall). Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.
| participants | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 0 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 3 | 0 | 2 | 3 | 1 |
| Day 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 3 | 0 |
| Day 8 | 0 | 0 | 0 | 1 | 4 | 4 | 3 | 2 | 1 | 0 | 2 | 0 | 1 |
| Day 15 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 29 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| percentage reduction | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT) | 5.0 | 25.9 | 26.7 | 35.5 | 61.5 | 77.2 | 83.1 | 81.1 | 87.9 | 0.78 | 43.1 | 77.7 | 7.2 |
Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.
| participants | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in > 100 Days | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 18 | 4 | 3 | 4 |
| percentage change | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serum interleukin-1 beta | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | -9 ± 17 | 9 ± 18 | 0 ± 0 | -2 ± 10 | 114 ± NA | 0 ± 0 |
| Serum interleukin-6 | 5 ± 8 | 79 ± 141 | 95 ± 113 | 50 ± 64 | 277 ± 308 | 100 ± 191 | 146 ± 261 | 258 ± 285 | 364 ± 255 | -1 ± 7 | 60 ± 52 | 130 ± NA | 56 ± 91 |
| Serum interleukin-8 | 32 ± 70 | 280 ± 328 | 336 ± 297 | 103 ± 101 | 1712 ± 981 | 564 ± 576 | 252 ± 363 | 695 ± 635 | 2015 ± 1569 | -6 ± 17 | 197 ± 319 | 46 ± NA | -44 ± 13 |
| Serum interleukin-10 | -5 ± 19 | 72 ± 134 | 51 ± 52 | 42 ± 45 | 27 ± 54 | 19 ± 28 | 116 ± 160 | 377 ± 498 | 638 ± 536 | -2 ± 7 | 0 ± 0 | 0 ± NA | -5 ± 8 |
| Serum interleukin-12p40 | 2 ± 37 | 2 ± 5 | 5 ± 8 | 6 ± 9 | 0 ± 0 | 0 ± 0 | 152 ± 217 | -9 ± 19 | 29 ± 38 | -3 ± 10 | -4 ± 13 | 79 ± NA | 0 ± 0 |
| Serum interleukin-12p70 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 54 ± 108 | 0 ± 0 | 0 ± 0 | 166 ± 389 | 82 ± 130 | -1 ± 4 | -3 ± 5 | 48 ± NA | 23 ± 40 |
| Serum monocyte chemoattractant protein-1 | 123 ± 171 | 442 ± 133 | 505 ± 254 | 632 ± 281 | 1176 ± 427 | 1297 ± 747 | 543 ± 497 | 906 ± 720 | 2014 ± 427 | 1 ± 13 | 262 ± 262 | 44 ± NA | -27 ± 14 |
| Serum macrophage inflammatory protein-1 alpha | 147 ± 126 | 294 ± 275 | 386 ± 556 | 264 ± 438 | 1674 ± 1022 | 1096 ± 578 | 406 ± 416 | 1003 ± 814 | 854 ± 538 | 15 ± 69 | 246 ± 304 | 0 ± NA | 0 ± 0 |
| Serum tumor necrosis factor alpha | 66 ± 69 | 207 ± 90 | 286 ± 90 | 187 ± 156 | 818 ± 344 | 476 ± 137 | 301 ± 237 | 761 ± 492 | 742 ± 273 | 3 ± 27 | 107 ± 152 | 55 ± NA | -29 ± 11 |
| Serum interferon alpha 2 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 4 ± 7 | 73 ± 147 | 172 ± 366 | 515 ± 529 | 5 ± 20 | -3 ± 7 | 700 ± NA | 69 ± 119 |
| percentage change | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Bb | 18 ± 16 | 56 ± 25 | 76 ± 37 | 133 ± 29 | 181 ± 185 | 137 ± 85 | 70 ± 63 | 147 ± 73 | 309 ± 174 | -7 ± 9 | 56 ± 61 | 59 ± NA | -14 ± 7 |
| Serum C3a | -12 ± 6 | 30 ± 42 | -22 ± 24 | -0 ± 8 | 71 ± 156 | -5 ± 18 | 14 ± 56 | 40 ± 50 | 34 ± 30 | -11 ± 23 | -18 ± 23 | 219 ± NA | 16 ± 40 |
| Serum C4a | -5 ± 7 | 37 ± 70 | -11 ± 10 | 2 ± 8 | 16 ± 13 | -8 ± 27 | 78 ± 107 | 60 ± 53 | -1 ± 15 | -19 ± 35 | -35 ± 21 | 160 ± NA | -15 ± 42 |
| Serum C5a | 2 ± 7 | 2 ± 7 | -16 ± 5 | -2 ± 25 | -14 ± 7 | 2 ± 15 | 0 ± 8 | 6 ± 6 | 6 ± 12 | -2 ± 18 | -4 ± 16 | 22 ± NA | -4 ± 10 |
| Serum CH50 | -5 ± 8 | -14 ± 11 | -14 ± 7 | -8 ± 8 | -16 ± 4 | -17 ± 8 | -10 ± 4 | -13 ± 13 | -19 ± 10 | -3 ± 9 | -3 ± 3 | -18 ± NA | -0 ± 13 |
Collected over Day -1 through Day 29 ± 1 day. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: 0.38 mg/kg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part A: 1.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part A: 2.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part A: 3.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part A: 4.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part A: 5.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part A: 6.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part A: 7.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part A: 8.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part A: Placebo | 0/18 (0%) | 1/18 (5.6%) | 9/18 (50%) |
| Part B: 2.0 mg/kg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part B: 4.0 mg/kg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part B: Placebo | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RhabdomyolosisMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/18 | 0/4 | 0/3 | 0/4 |
| Event | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ChillsGeneral disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 3/4 | 0/18 | 0/4 | 0/3 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 1/4 | 0/4 | 1/4 | 1/4 | 1/18 | 0/4 | 0/3 | 1/4 |
| HeadacheNervous system disorders | 1/4 | 1/4 | 0/4 | 0/4 | 1/4 | 2/4 | 2/4 | 0/4 | 0/4 | 0/18 | 1/4 | 0/3 | 1/4 |
| MigraineNervous system disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 | 0/18 | 0/4 | 1/3 | 0/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/18 | 0/4 | 1/3 | 1/4 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/18 | 0/4 | 1/3 | 0/4 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/18 | 0/4 | 1/3 | 0/4 |
| ConjunctivitisInfections and infestations | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/18 | 0/4 | 0/3 | 0/4 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/18 | 0/4 | 0/3 | 0/4 |
| ParaesthesiaNervous system disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/18 | 1/4 | 0/3 | 0/4 |
| Age, Continuous(years) | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 39.0 ± 9.8 | 25.0 ± 4.5 | 30.0 ± 7.8 | 29.5 ± 10.7 | 32.3 ± 5.6 | 23.8 ± 4.1 | 32.5 ± 15.3 | 26.0 ± 5.0 | 25.0 ± 1.8 | 25.4 ± 4.8 | 59.0 ± 1.8 | 64.3 ± 3.8 | 58.8 ± 9.0 | 33.4 ± 14.3 |
| Sex: Female, Male(Participants) | Part A: 0.38 mg/kg | Part A: 1.0 mg/kg | Part A: 2.0 mg/kg | Part A: 3.0 mg/kg | Part A: 4.0 mg/kg | Part A: 5.0 mg/kg | Part A: 6.0 mg/kg | Part A: 7.0 mg/kg | Part A: 8.0 mg/kg | Part A: Placebo | Part B: 2.0 mg/kg | Part B: 4.0 mg/kg | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 4 | 2 | 1 | 1 | 4 | 3 | 3 | 2 | 12 | 3 | 1 | 3 | 40 |
| Male | 3 | 0 | 2 | 3 | 3 | 0 | 1 | 1 | 2 | 6 | 1 | 2 | 1 | 25 |
The record gives a start of Feb 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
alpha 1-Antitrypsin Deficiency →